search
Back to results

Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases

Primary Purpose

Meningeal Carcinomatosis

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
lumbar puncture
Sponsored by
The Netherlands Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Meningeal Carcinomatosis focused on measuring CTC, cytology, meningeal carcinomatosis, leptomeningeal metastases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who are treated for advanced EpCam positive solid tumors (such as breast cancer, lung cancer, gastrointestinal cancer)
  • Age >= 18 years;
  • Able and willing to give written informed consent;
  • WHO performance status (0, 1, 2, 3 or 4);
  • Able and willing to undergo lumbar puncture and veni-puncture.

Exclusion Criteria:

  • Lumbar puncture not clinically / diagnostically indicated

Sites / Locations

  • Dutch Cancer Institute - Antoni van Leeuwenhoek
  • Slotervaart Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

diagnostic

Arm Description

Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.

Outcomes

Primary Outcome Measures

Determine the sensitivity and specificity of detection of circulating tumor cells (CTCs) in patients with Epcam expressing tumors compared to cytology in the cerebrospinal fluid of patients, clinically suspected for leptomeningeal metastases

Secondary Outcome Measures

- To determine the relationship between the number of CTCs in CSF and the patient's neurological condition and WHO performance score
- To determine the change in the CTC number between two sampling points and correlate this with the patient's neurological condition and therapy
- To determine the relationships between demographics/tumor status and CTCs number in CSF.
- To determine the relationship between the CTC cells in the CSF and the CTCs in the peripheral blood
To confirm EPCAM positivity in archived primary tumor tissue and tumorcells in CSF.
- To compare the predictive value of two CTC enumeration methods

Full Information

First Posted
October 22, 2012
Last Updated
January 19, 2021
Sponsor
The Netherlands Cancer Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01713699
Brief Title
Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases
Official Title
Determining the Sensitivity and Specificity of Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
September 6, 2016 (Actual)
Study Completion Date
September 19, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Netherlands Cancer Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether the quantitative detection of circulating tumor cells (CTCs) in patients with Epcam expressing tumors can be used compared to standard qualitative method - cytology both in the cerebrospinal fluid of patients, clinically suspected for leptomeningeal metastases.
Detailed Description
Leptomeningeal metastases (LM), is a diffuse dissemination of tumor cells into the cerebrospinal fluid (CSF) and leptomeninges.[1] Up to 8% of all patients with cancer develop LM. Gadolinium enhanced MRI of the symptomatic location of the nervous system is the radiological method of choice when LM is clinically suspected. In patients with a metastasized tumor, based on clinical signs of LM and contrast enhancement of either the leptomeninges, pia mater/cortex or cranial or spinal nerves on MRI, the diagnosis LM can be made. The sensitivity of MRI with gadolineum for LM is 75% and the specificity 77%. If MRI does not show equivocal abnormalities, CSF cytology needs to be performed. In 55% of patients with LM from solid tumors, malignant cells are found during the first CSF examination. The sensitivity raises to 80-90% after the second CSF sampling, as determined in the pre-MRI era. The volume of sampled CSF determines partly the sensitivity of CSF cytology. If possible, 10 ml CSF needs to be taken and the material must be processed as quickly as possible. Recently, Patel et al (2011) described the detection of breast cancer cells in the CSF using the Cell Search System (Veridex). [6] Using this method, the CSF is enriched immuno-magnetically for the epithelial cell adhesion molecule (EpCAM). Next nuclear staining with 4 ',6-diamidino-2-phenylindole (DAPI) and immunofluorescent detection with cytokeratin and CD45 is performed in 5 patients with leptomeningeal metastases from breast cancer and approximately 104 circulating tumor cells (CTCs)in 7,5 ml CSF were found, using this method. There seemed to be an association between the number of CTCs and response to intrathecal administered chemotherapy in this small group of patients. In the future, the determination of CTCs in the CSF could be a new quantitative method for the anti-tumor response assessment of systemic or intrathecal therapy (as opposed to CSF cytology, which is subjective and not a quantitative method). If the method shows greater sensitivity than CSF cytology and can reliably measure single tumor cells, the sensitivity of CSF examination in patients with a clinical suspicion of LM will increase. Possibly, this method can also be used to detect micrometastases in the CSF in patients without neurological symptoms, but with a high risk of CNS metastases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meningeal Carcinomatosis
Keywords
CTC, cytology, meningeal carcinomatosis, leptomeningeal metastases

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
146 (Actual)

8. Arms, Groups, and Interventions

Arm Title
diagnostic
Arm Type
Other
Arm Description
Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
Intervention Type
Procedure
Intervention Name(s)
lumbar puncture
Primary Outcome Measure Information:
Title
Determine the sensitivity and specificity of detection of circulating tumor cells (CTCs) in patients with Epcam expressing tumors compared to cytology in the cerebrospinal fluid of patients, clinically suspected for leptomeningeal metastases
Time Frame
3 months after end of study
Secondary Outcome Measure Information:
Title
- To determine the relationship between the number of CTCs in CSF and the patient's neurological condition and WHO performance score
Time Frame
3 months after end of study
Title
- To determine the change in the CTC number between two sampling points and correlate this with the patient's neurological condition and therapy
Time Frame
3 months after end of study
Title
- To determine the relationships between demographics/tumor status and CTCs number in CSF.
Time Frame
3 months after end of study
Title
- To determine the relationship between the CTC cells in the CSF and the CTCs in the peripheral blood
Time Frame
3 months after end of study
Title
To confirm EPCAM positivity in archived primary tumor tissue and tumorcells in CSF.
Time Frame
3 months after end of study
Title
- To compare the predictive value of two CTC enumeration methods
Time Frame
3 months after end of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who are treated for advanced EpCam positive solid tumors (such as breast cancer, lung cancer, gastrointestinal cancer) Age >= 18 years; Able and willing to give written informed consent; WHO performance status (0, 1, 2, 3 or 4); Able and willing to undergo lumbar puncture and veni-puncture. Exclusion Criteria: Lumbar puncture not clinically / diagnostically indicated
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
D. Brandsma, MD, PhD
Organizational Affiliation
NKI-AvL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dutch Cancer Institute - Antoni van Leeuwenhoek
City
Amsterdam
ZIP/Postal Code
1066CX
Country
Netherlands
Facility Name
Slotervaart Hospital
City
Amsterdam
ZIP/Postal Code
1066EC
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
26566655
Citation
Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D. EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro Oncol. 2016 Jun;18(6):855-62. doi: 10.1093/neuonc/nov273. Epub 2015 Nov 12.
Results Reference
derived
Links:
URL
http://www.nki.nl/Research
Description
NKI-AVL

Learn more about this trial

Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases

We'll reach out to this number within 24 hrs